Welcome to our dedicated page for Aurora Cannabis SEC filings (Ticker: ACB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aurora Cannabis Inc. filings document its U.S. reporting as a Canadian foreign private issuer and the formal disclosure record for its medical cannabis operations. Recent Form 6-K reports furnish news releases, material change reports, sales agreements and offering documents tied to product launches, financial results, acquisitions, governance matters and capital-structure activity.
The filings include disclosure for an at-the-market common-share program under shelf registration documents, material change reports on corporate transactions, and exhibits incorporated by reference into Form F-10 and Form S-8 registration statements. They also record Aurora's operating updates across regulated cannabis markets, GMP-certified manufacturing network, shareholder voting matters and executive-level governance disclosures.
Aurora Cannabis reported record fiscal 2026 results but a softer Q4 and a cautious outlook. Full-year total net revenue was $320.6 million, driven by record global medical cannabis net revenue of $288.6 million, up 18% year over year. Full-year adjusted EBITDA reached a record $53.8 million, up 32%.
In Q4 2026, total net revenue rose 10% year over year to $84.8 million, led by a 14% increase in medical cannabis net revenue to $77.1 million, which generated 91% of consolidated net revenue. However, Q4 adjusted EBITDA declined to $9.2 million from $14.1 million, and net loss from continuing operations widened to $27.6 million.
The company completed the accretive $26.5 million acquisition of Safari Flower Company, adding a 59,000 sq ft EU‑GMP certified facility to support international growth, and exited its Bevo plant propagation stake. Aurora ended Q4 with approximately $164.7 million in cash, short-term investments and cash equivalents and no debt, and working capital of $330.5 million.
Looking to fiscal 2027, Aurora expects total net revenue to decline toward fiscal 2025 cannabis levels and anticipates lower annual adjusted EBITDA, even as adjusted gross margins are guided to the mid‑to‑high 50% range and adjusted SG&A is expected to remain broadly in line with the prior year.
Aurora Cannabis Inc. files its Annual Report on Form 40-F reporting corporate governance, controls, auditor information and exhibits for the fiscal year ended March 31, 2026. The report states 58,947,593 common shares outstanding as of the close of the period and discloses auditor fees and governance committee composition.
The filing incorporates audited consolidated financial statements, MD&A and an Annual Information Form as exhibits and includes forward-looking statements about operations, financing and strategic matters.
Aurora Cannabis Inc. will report its fourth quarter and fiscal year 2026 financial results and host an investor conference call on Thursday, June 11, 2026. The company plans to release results before markets open that day, followed by a call at 8:00 a.m. Eastern Time.
Chief Executive Officer Miguel Martin and Chief Financial Officer Simona King will lead the call and question-and-answer session. The announcement reiterates Aurora’s focus on global medical cannabis markets and includes standard forward-looking statement language referencing risk factors outlined in its June 17, 2025 annual information form.
Aurora Cannabis Inc. is organizing its next annual general meeting of security holders and has outlined key dates and logistics. The meeting will be held as a virtual event on August 07, 2026, allowing shareholders to participate online.
The record date for notice of meeting, record date for voting, and beneficial ownership determination date are all set at June 15, 2026. The company will use notice-and-access for both registered and beneficial holders, and will pay for delivery of proxy materials to objecting beneficial owners.
Aurora Cannabis Inc. reported that it has been granted Plant Breeders' Rights in Canada for two proprietary cannabis cultivars developed through its internal breeding program. These rights give Aurora exclusive authority to grow, propagate, and sell finished products from these specific varieties in Canada.
The protected cultivars are SOT20R07-007, marketed as Farm Gas™, and SOT20R07-005, marketed as Driftwood Diesel™, developed at the Aurora Coast research facility in British Columbia. These strains are core medical cannabis products available to patients in Germany, Poland, the UK, Canada, and Australia, and Aurora states that this protection, alongside recent European variety protection, enhances its global competitive position in medical cannabis.
Aurora Cannabis Inc. is expanding its global medical cannabis portfolio with new product launches across Canada, Europe and Australia. The rollout, occurring between now and June, adds dried flower, pre-rolls and precisely dosed pastilles that align with the company’s medical-first strategy and GMP-certified production network.
New offerings in Germany and Poland broaden high-THC dried flower choices, while Australian launches introduce discreet, long-lasting pastilles featuring multiple cannabinoids. In Canada, Aurora is adding new dried flower and pre-roll products under its WMMC and San Raf brands, aiming to meet patient and prescriber demand in regulated medical markets.
Aurora Cannabis Inc. reported that a wholly owned subsidiary, Aurora Sub, has indirectly purchased 100% of the shares of 9869247 Canada Limited (Safari Flower Company), an established EU GMP certified cannabis cultivator and manufacturer.
The aggregate consideration for the Safari Flower Company transaction is valued at $26.5 million, which includes a $2 million cash payment that is contingent on certain conditions. At closing, Aurora issued the selling shareholder 2,417,180 common shares and paid $15 million in cash, with amounts subject to customary post-closing adjustments.
Aurora Cannabis Inc. has acquired Safari Flower Company for aggregate consideration valued at $26.5 million. The deal includes 2,417,180 common shares, $15 million in cash at closing, and an additional $2 million cash payment contingent on certain conditions.
Safari Flower operates a 59,000 square foot EU GMP certified indoor cultivation and manufacturing facility in Ontario, which will add tightly aligned capacity to Aurora’s existing network. Aurora plans to use this expanded EU GMP capacity to supply high-margin international medical cannabis markets such as Germany, Australia, Poland, and the UK.
The company expects the acquisition to contribute positively to Adjusted EBITDA in fiscal year 2027, with incremental benefits in fiscal 2028 and beyond as operations are optimized, leveraging Aurora’s plant science and operational expertise.
Aurora Cannabis Inc. filed a Form 6-K highlighting that it has been named to The Globe and Mail’s 2026 Women Lead Here list for the second consecutive year. This editorial benchmark recognizes publicly traded Canadian companies with strong executive-level gender diversity.
Aurora is one of 85 companies on the list with 50% female representation on its executive leadership team, underscoring its stated focus on developing a diverse pipeline of female talent and fostering an inclusive leadership culture. The company positions this recognition as aligned with its broader commitment to people, patients, and communities it serves across global medical cannabis markets.
Aurora Cannabis Inc. filed a report highlighting two main updates. The company will participate in TD Cowen's 46th Annual Health Care Conference in Boston, where CFO Simona King will join a fireside chat and investor meetings on March 2, 2026.
Aurora also announced it has completed its previously announced transaction with Bevo Agtech Inc., referred to as the Bevo Transaction. Further details of this transaction are available in the company’s February 4, 2026 press release on SEDAR+.